Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | RASSF2 |
| Gene Name: | RASSF2 |
| Protein Full Name: | Ras association domain-containing protein 2 |
| Alias: | KIAA0168; Ras association (RalGDS/AF-6) domain family member 2; Ras association domain family 2; RASF2; Rasfadin |
| Mass (Da): | 37790 |
| Number AA: | 326 |
| UniProt ID: | P50749 |
| Locus ID: | 9770 |
| COSMIC ID: | RASSF2 |
| Gene location on chromosome: | 20p13 |
| Cancer protein type: | TSP |
| Effect of cancer mutation on protein: | LOSS |
| Effect of active protein on cancer: | INHIBITS |
| Number of cancer specimens: | 19969 |
| Percent of cancer specimens with mutations: | 0.57 |
| Gene undergoes hypermethylation: | CpG island DNA hypermethylation in colorectal cancer (42-70% in colorectal carcinomas; 25-94% in adenomas); NSCLC (44-62%) (22/50, 16/26); SCLC (18%) (4/22); nasopharyangeal carcinoma (51%) (27/53); gastric cancer (29-79%) (23/78, 62/78); prostate cancer; |
| Normal role description: | RASSF2 belongs to the RASSF family of tumour suppressor genes and encode for a Ras superfamily effector protein that mediates certain growth inhibitory functions of Ras proteins by functioning as a K-Ras adaptor protein. It regulates apoptosis and cell cycle progression through interactions with downstream effectors such as MST1 and MST2. Promoter DNA hypermethylation and inactivation of RASSF2 have been described in several cancers, and the protein is hence believed to function as a tumour suppressor. |
| Commentary on involvement of protein in cancer: | 2/200 lung cancer samples were also mutated (Sanger COSMIC) |